Clinical Trial

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine how safe and tolerable the RP2CD of JNJ-7827834 and JNJ-95298177 with or without JNJ-87189401 is for treatment of participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of prostate cancer where the cancer has spread beyond the prostate and is resistant to hormonal therapy) in Part 2 (Dose expansion) of study.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2025-07-22; most recent amendment 2026-07-02.
Status change: Not Yet Recruiting → Recruiting 2025-08-14
Trial Details
NCT Number NCT07082920
Lead Sponsor Janssen Research & Development, LLC
Conditions Prostatic Neoplasms
Enrollment 140 participants
Start Date 2025-07-07
Primary Completion 2027-01-28 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-13